{"filings":[{"id":91749,"accession_number":"0000012208-26-000034","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.","GAAP net loss $527.1M (diluted EPS -$19.55) vs prior-year net income $64.0M ($2.29).","Non-GAAP net income $50.9M ($1.89 diluted EPS); non-GAAP operating income $39.3M, down from $63.0M.","Operating cash flow $108.1M; free cash flow $78.1M; repurchased ~176k shares during Q1.","Management cited challenging academic markets and Middle East conflict as headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-19.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":592100000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91748,"accession_number":"0000012208-26-000024","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Amended 2017 Incentive Award Plan, adding 335,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan approved with 6.85M for, 105k against; extends expiration to March 18, 2036.","Increases share reserve by 335,000 shares for future equity grants.","Stockholder proposal on dual-class capital structure defeated (1.47M for, 5.46M against).","All six director nominees elected; KPMG ratified as auditors for FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102039,"accession_number":"0000012208-26-000012","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad updates Sartorius AG 2025 financials: sales €3.54B, net profit €230M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG 2025: sales €3,538.1M, gross profit €1,636.7M, EBIT €542.6M, net profit €230.4M.","Balance sheet: current assets €1,766.2M, non-current €7,951.1M, total equity €3,867.2M.","Operating cash flow €837.0M; investing outflow €513.7M; financing outflow €591.4M.","Update follows Sartorius’ Feb 16, 2026 release; Bio-Rad’s 10-K investment disclosure updated accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102038,"accession_number":"0000012208-26-000007","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.","Q4 non-GAAP operating income $83.0M (down 10% YoY); non-GAAP EPS $2.51 vs $2.90.","Full-year non-GAAP operating income $311.6M vs $331.3M; EPS $9.92 vs $10.31.","Q4 GAAP net income $720.0M vs $715.8M loss YoY driven by equity investment fair value changes.","CEO cites geopolitical uncertainty and academic funding pressure; Stilla acquisition integrated."],"consensus_eps_estimate":null,"consensus_eps_actual":27.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":2583200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118395,"accession_number":"0000012208-25-000076","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $653.0M, up slightly from $649.7M year-over-year.","GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.","Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.","GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.","CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1890000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134822,"accession_number":"0000012208-25-000057","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad co-founder and Director Emeritus Alice Schwartz dies at 99","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alice N. Schwartz, co-founder of Bio-Rad, passed away on September 25, 2025, at age 99.","She co-founded Bio-Rad in 1952 with her husband David and developed the company's first thyroid test kit in the 1960s.","Schwartz served as an active Board member until 2022 and was named Director Emeritus.","Her contributions included the innovation that marked Bio-Rad's entry into clinical diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134821,"accession_number":"0000012208-25-000054","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad holds ddPCR webinar; no new financial or product details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Informational webinar on Droplet Digital PCR portfolio held August 26, 2025.","President/COO Jon DiVincenzo and CFO Roop Lakkaraju hosted the event.","Slide presentation and replay posted on investor relations page for one year.","No specific product performance, revenue, or guidance figures provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134820,"accession_number":"0000012208-25-000051","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).","Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.","GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.","Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems."],"consensus_eps_estimate":null,"consensus_eps_actual":13.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":1237000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134819,"accession_number":"0000012208-25-000047","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Rad appoints Rajat Mehta as EVP Global Commercial Operations; Crowley retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajat Mehta appointed EVP, Global Commercial Operations, effective August 4, 2025.","Mehta joins from Labcorp (SVP) and Thermo Fisher Scientific; holds Wharton MBA.","Mike Crowley retiring after 26 years; will stay as employee through September 2025 for transition.","Board approved change on July 23, 2025; Crowley ceases as executive officer on August 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151746,"accession_number":"0000012208-25-000032","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio-Rad completes acquisition of Stilla Technologies on June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Affiliate of Bio-Rad completed purchase of all equity interests of Stilla Technologies, a French corporation.","Transaction was previously announced on February 13, 2025.","No financial terms of the acquisition were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151745,"accession_number":"0000012208-25-000025","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.","GAAP net income $64.0M ($2.29 EPS) vs $383.9M ($13.45 EPS) in Q1 2024.","Non-GAAP net income $71.0M ($2.54 EPS) vs $65.3M ($2.30 EPS) YoY.","CEO cites market uncertainty; moderating full-year 2025 outlook.","Non-GAAP gross margin 53.8%, slightly down from 54.2% a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":585400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151744,"accession_number":"0000012208-25-000022","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Rad shareholders elect directors, ratify KPMG, reject severance proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Litherland, Pinkston (Class A); Edwards, Hinckley, A. Schwartz, N. Schwartz (Class B).","Ratification of KPMG as independent auditor for FY2025 approved: 7,151,391 for, 51,910 against, 2,176 abstain.","Stockholder proposal on executive severance approval failed: 923,215 for, 6,125,784 against, 3,277 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170604,"accession_number":"0000012208-25-000009","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad discloses Sartorius AG FY2024 results: revenue €3.38B, net profit €137.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG reported FY2024 sales revenue of €3,380.7M, gross profit €1,524.4M, EBIT €392.6M.","Net profit for FY2024 was €137.4M; operating cash flow €976.2M, investing cash flow -€425.8M.","As of Dec 31, 2024, Sartorius had total assets €10,103.0M, total liabilities €6,205.2M, equity €3,897.8M.","Bio-Rad does not assume responsibility for Sartorius's publicly disclosed figures; refers to Sartorius's annual report.","Update relates to Bio-Rad's Investment in Sartorius AG section of its 2024 10-K filed Feb 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170603,"accession_number":"0000012208-25-000004","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.","Full-year 2024 revenue $2,566.5M vs $2,671.2M; non-GAAP op margin 12.9% vs 14.2%.","Restructuring plan eliminates ~5% of workforce; expected cost $45-50M, $30-35M charge in Q1 2025.","Binding offer to acquire all equity of Stilla Technologies (digital PCR); close expected by Q3 2025.","No deal value disclosed; acquisition subject to regulatory approvals and employee consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187587,"accession_number":"0000012208-24-000062","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.","Life Science segment sales $260.9M, -1.0% YoY, citing ongoing biotech/biopharma weakness.","Income from operations fell to $64.5M from $90.9M; net income surged to $653.2M ($23.34 EPS) on Sartorius fair value change.","Gross margin improved to 54.8% from 53.1% YoY; effective tax rate 24.2%.","Appointed Jon DiVincenzo as President and COO; CEO cites gradual biopharma recovery and new leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":-39.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1899025000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204077,"accession_number":"0000012208-24-000056","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bio-Rad amends bylaws to update stockholder meeting procedures and proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended Bylaws effective Sept 6, 2024, adding electronic stockholder meeting participation and universal proxy rule compliance.","Eliminated requirement to make stockholder list available at meetings.","Clarified CEO role as separate from President; required proxy solicitors to use non-white proxy card color.","Updated procedures for director nominations and other business proposals, including Rule 14a-19 universal proxy rules.","Made other administrative, clarifying, and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204076,"accession_number":"0000012208-24-000054","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Rad appoints Jon DiVincenzo as President and COO, replacing retiring Andy Last","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["DiVincenzo joins from Labcorp, where he was EVP and President, Central Laboratories & International.","Start date September 9, 2024; Last retires September 5, 2024.","Compensation includes $665k base salary, $2.5M RSU grant, $1.3M sign-on bonus, and relocation support.","Norman Schwartz remains CEO and Chairman, no longer President.","DiVincenzo brings 30+ years of life science and diagnostics experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204075,"accession_number":"0000012208-24-000050","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).","Gross margin improved to 55.6% from 53.2%; operating income $101.5M vs $89.6M YoY.","Net loss $2,165.5M ($76.26 diluted EPS) mainly due to non-cash fair value adjustment of Sartorius investment.","CEO expects more modest pace of market recovery than originally anticipated.","Board authorized additional $500M share repurchase; total available ~$578M as of July 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-62.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1249296000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220778,"accession_number":"0000012208-24-000036","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.","Life Science segment $241.7M (-25.3% YoY) due to biotech/biopharma weakness; Clinical Diagnostics $368.6M (+4.7%) grew.","Net income $383.9M ($13.45 diluted) vs $69.0M ($2.32), largely from fair value changes of Sartorius AG equity holdings.","CEO Norman Schwartz: Q1 in line with expectations; cautiously optimistic for gradual biopharma recovery in H2 2024.","Effective tax rate 21.8% vs 18.7% a year ago, affected by equity securities treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":13.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":610820000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220777,"accession_number":"0000012208-24-000031","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Bio-Rad Life Science Group President Simon May resigns; James Barry appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon May resigns as EVP & President, Life Science Group, effective May 1, 2024, to pursue another opportunity.","James J. Barry promoted from SVP of Global Manufacturing to succeed May as EVP & President, Life Science Group, effective May 1, 2024.","Stockholders approved amendment to 2017 Incentive Award Plan, extending expiration to 2034 and allowing non-employee director participation.","Principal accounting officer role transferred to CFO Roop K. Lakkaraju, replacing interim Tania DeVilliers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220776,"accession_number":"0000012208-24-000025","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Rad COO Andrew Last to retire by early September 2024; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Andrew Last notified Bio-Rad of his retirement from EVP and COO role on April 10, 2024.","He will remain in his position through early September to ensure a smooth transition.","CEO Norman Schwartz credited Last with progress on cost structure, core processes, and supply chain.","Bio-Rad has started a search for Last's successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240393,"accession_number":"0000012208-24-000018","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Rad appoints Roop K. Lakkaraju as EVP, CFO effective April 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roop K. Lakkaraju joins from Benchmark Electronics, where he was EVP & CFO since 2018.","Annual base salary $600,000; 2024 target cash bonus 75% of eligible earnings.","RSU grant valued at $1,450,000 within 60 days of hire; 2024 LTI target $2,000,000.","Severance of 18 months base salary if terminated without cause, subject to release.","Housing and relocation credit of $20,000; no family relationships or material interests disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240392,"accession_number":"0000012208-24-000015","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad discloses Sartorius AG FY 2023 results: revenue €3.4B, net profit €290M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG FY 2023 sales revenue €3,395.7M, gross profit €1,567.1M.","EBIT €503.9M, net profit €290.0M for the year ended Dec 31, 2023.","Operating cash flow €853.6M; investing cash flow -€2,823.3M; financing cash flow €2,165.7M.","Total assets €9,755.4M, equity €2,757.4M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240391,"accession_number":"0000012208-24-000008","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q4 sales down 6.7% YoY; Life Science segment declines 19.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $681.2M, down 6.7% YoY; currency-neutral sales down 7.7%.","Life Science segment sales $291.1M, down 19.1% YoY on broad-based weakness.","Clinical Diagnostics segment sales $389.0M, up 5.3% YoY on diabetes and quality control demand.","Net income $349.7M ($12.14 diluted EPS) vs $827.7M ($27.78) a year ago, impacted by Sartorius fair value changes.","CEO cites ongoing biopharma weakness; expects gradual recovery in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-21.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":2671300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240390,"accession_number":"0000012208-24-000005","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","1.02","2.03","5.02","9.01"],"status":"ready","headline":"Bio-Rad enters $200M credit facility; CEO Schwartz appointed interim CFO after Daskal departure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $200M revolving credit facility with Wells Fargo, matures Feb 13, 2029; replaces prior $200M facility.","CFO Ilan Daskal resigned effective Nov 6, 2023; CEO Norman Schwartz appointed interim principal financial officer on Feb 9, 2024.","Facility includes leverage ratio covenant of 3.50x; interest rates based on SOFR plus margin.","Outstanding obligations under prior credit agreement repaid in full on Feb 14, 2024 with no penalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257903,"accession_number":"0000012208-23-000074","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bio-Rad EVP & President of Clinical Diagnostics Group to resign effective Jan 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dara Grantham Wright notified resignation to pursue another opportunity, effective Jan 12, 2024.","Wright served as EVP, President of Clinical Diagnostics Group and was a named executive officer.","Company has initiated a search for her replacement; no successor named yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257902,"accession_number":"0000012208-23-000068","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q3 net sales down 7.1% YoY to $632.1M; lowers full-year 2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $632.1M, down 7.1% YoY; currency-neutral decline 7.9%; COVID sales dropped to $0.3M from $17.2M.","Life Science segment sales $263.5M, down 17.1% YoY (currency-neutral -17.8%); diagnostics segment up 1.7%.","Net income $106.3M ($3.64 diluted EPS) vs net loss of $162.8M ($5.48 loss) in prior year, driven by Sartorius fair value changes.","Operating income $90.9M vs $94.6M; gross margin 53.1% vs 54.7%.","CEO cites further deterioration in biopharma/biotech spending and China challenges; full-year FY2023 outlook lowered."],"consensus_eps_estimate":null,"consensus_eps_actual":-33.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":1990078000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257901,"accession_number":"0001193125-23-257773","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bio-Rad CFO Ilan Daskal to resign effective Nov 6, 2023; search initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Ilan Daskal notified Bio-Rad of his resignation to pursue another opportunity.","Resignation effective at close of business on November 6, 2023.","Company has initiated a search for a new CFO; no successor named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275235,"accession_number":"0000012208-23-000065","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bio-Rad CAO Ajit Ramalingam resigns; interim principal accounting officer appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ajit Ramalingam, SVP and Chief Accounting Officer, resigns effective Sept 18, 2023.","Tania DeVilliers, Senior Director, Corporate Controller, named interim principal accounting officer.","DeVilliers is a CPA and Chartered Accountant with over 25 years of experience, formerly at PwC.","Company has initiated a search for a permanent successor; interim compensation to be determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275234,"accession_number":"0000012208-23-000062","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q2 net loss $1.16B on investment swings; lowers FY2023 outlook on softer biopharma demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $681.1M, down 1.4% (0.3% currency-neutral); ex-COVID revenue up 4.6% currency-neutral.","Life Science segment sales $300.2M (-6.9%); ex-COVID growth 4.5% driven by ddPCR/qPCR.","Clinical Diagnostics sales $380.1M (+3.3%); ex-COVID growth 4.8% on diagnostic systems and quality control.","Operating income $89.6M vs $122.9M; net loss $1,162.3M ($39.59/sh) primarily from Sartorius AG fair value changes.","CEO lowers FY2023 expectations due to softer demand from large biopharma and persistent early-stage biotech weakness."],"consensus_eps_estimate":null,"consensus_eps_actual":-37.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1357954000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275233,"accession_number":"0000012208-23-000058","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Rad authorizes new $500M share repurchase program, superseding prior $650M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $500M in common stock repurchases; no time limit.","Prior $650M repurchase program was completed on June 5, 2023.","Repurchases at management's discretion on open market or privately.","Acquired shares for employee stock plans, acquisitions, and dilution offset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292684,"accession_number":"0000012208-23-000054","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad completes $650M share repurchase program; plans additional authorization in Q3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2-to-date repurchased $207.4M of Class A common stock, 549,863 shares at avg $377.20.","Aggregate repurchases reach the $650M limit authorized by Board in Nov 2017, July 2020, and July 2022.","Management intends to seek Board approval for additional repurchase authority in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292683,"accession_number":"0000012208-23-000045","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.","GAAP diluted EPS $2.32 vs loss of $112.50; operating income $61.9M vs $146.4M.","Life Science sales $323.6M, down 6.8% (ex-COVID up 9.6% on qPCR, western blotting, ddPCR).","Clinical Diagnostics sales $352.1M flat; currency-neutral up 2.8% ex-COVID up 3.1%.","COVID sales dropped to $2.6M from $45M; gross margin fell to 53.5% from 57.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":676844000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292682,"accession_number":"0000012208-23-000041","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Rad annual meeting results: directors elected, say-on-pay approved, political disclosure rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees elected; Melinda Litherland and Arnold Pinkston (Class A) each >73% of votes cast.","KPMG ratified as auditor for FY2023 with 7.26M votes for, 19.7K against.","Non-binding advisory vote on executive compensation approved (6.77M for, 277K against).","Advisory frequency set at three years (5.46M votes for three years vs 1.58M for one year).","Stockholder proposal on political disclosure defeated: 5.94M against, 1.10M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313330,"accession_number":"0000012208-23-000035","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad discloses Sartorius AG 2022 financials: sales €4.17B, net profit €913M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sartorius AG reported 2022 sales revenue of €4,174.7M and gross profit of €2,196.5M.","EBIT of €1,064.8M and net profit of €913.1M for the year ended December 31, 2022.","Cash flow from operations €734.2M; investing activities used €1,129.9M.","Total equity at year-end €2,658.9M; current assets €2,023.2M, current liabilities €1,803.4M.","Data sourced from Sartorius's IFRS consolidated financial statements publicly disclosed on Feb 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313329,"accession_number":"0000012208-23-000025","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).","Life Science segment $359.7M (+10.1%); Clinical Diagnostics $369.6M (-8.7%).","GAAP net income $827.7M ($27.78 diluted) from Sartorius fair value; non-GAAP net income $98.5M ($3.31).","Full-year 2022 net sales $2,802.2M (-4.1%); non-GAAP EPS $14.42 vs $15.94 prior year.","FY2023 outlook: non-GAAP currency-neutral revenue growth ~6-7%, non-GAAP operating margin ~19.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":-121.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":2802200000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313328,"accession_number":"0000012208-23-000009","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad to present at J.P. Morgan Healthcare Conference on Jan 10, 2023","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["President & CEO Norman Schwartz to present company overview at 4:30 p.m. PT.","Q&A session with EVP/COO Andrew Last and EVP/CFO Ilan Daskal.","Webcast link available on investor relations section of bio-rad.com.","No specific financial results or material disclosures provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331855,"accession_number":"0000012208-22-000080","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad repurchases $67.1M of Class A shares QTD through Nov 8, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Remaining repurchase authorization: $231.0M as of Nov 8, 2022.","QTD repurchases: $67.1M at avg price $368.40/share (182,228 shares).","Previous remaining at Sept 30, 2022 was $298.1M.","Buybacks under program authorized by board in Nov 2017, Jul 2020, Jul 2022 for up to $650M total."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331854,"accession_number":"0000012208-22-000065","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.","GAAP net loss $164.2M ($5.52 loss per diluted share) vs income $3,928M in Q3 2021, driven by Sartorius fair-value swings.","Non-GAAP net income $77.9M ($2.60 diluted EPS) vs $112.2M ($3.71) in Q3 2021.","Life Science segment sales $317.9M (-14.9% YoY); Clinical Diagnostics $361.9M (-2.8% YoY; +3.0% currency-neutral).","FY22 guidance: non-GAAP currency-neutral revenue growth at high end of prior 1.0-2.0%; COVID revenue now ~$105M; operating margin ~19.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":-149.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":2071961000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349324,"accession_number":"0000012208-22-000040","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Rad Q2 revenue $691M down 3.5% YoY; non-GAAP EPS $3.38; raises FY22 revenue outlook; adds $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP net loss $927M ($31.12/diluted) vs income $914M ($30.32) last year; non-GAAP net income $101M ($3.38) vs $107M ($3.54).","Reported sales $691.1M down 3.5% YoY; currency-neutral core sales (ex-COVID) up 5.7%.","Life Science $322M (-3.5% reported, +0.5% constant); Clinical Diag $368M (-3.3%, +0.7% constant).","FY22 guidance: non-GAAP currency-neutral revenue growth at high end of 1-2%; COVID rev ~$93M (up); op margin ~19% reaffirmed.","Board authorized additional $200M share repurchase; total available $298.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-143.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1391161000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366232,"accession_number":"0001193125-22-154095","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Rad updates share repurchase activity: $125M repurchased QTD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quarter-to-date through May 17, 2022, Bio-Rad repurchased $125M of Class A common stock.","Repurchased 255k shares at an average price of $489.65 per share.","Total repurchased under program: $351.9M; remaining authorization: $98.1M.","Buyback program authorized Nov 2017 for $250M, increased by $200M in July 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366231,"accession_number":"0000012208-22-000021","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.","Life Science segment sales $347.2M (-5.3% YoY); Clinical Diagnostics $351.8M (-1.9%).","Full-year 2022 outlook: non-GAAP currency-neutral revenue growth ~1-2%; op margin ~19%.","COVID-related revenue fell to ~$45M vs $94M in Q1 2021; core business grew 6.5% currency-neutral.","Management notes macro risks: China lockdowns, Ukraine war, supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":-112.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":700062000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366230,"accession_number":"0001193125-22-111203","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bio-Rad amends credit agreement to exclude cash over $200M from leverage ratio","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 2 redefines Leverage Ratio to deduct cash and cash equivalents exceeding $200M from total funded debt.","Section 6.1 reporting deadlines extended: annual financials to 120 days (from 90) and quarterly to 60 days (from 45).","Amendment effective April 15, 2022; no defaults or new borrowing; lenders include JPMorgan, Bank of America, HSBC, and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385720,"accession_number":"0001193125-22-086770","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Co-founder Alice Schwartz to leave Bio-Rad board; appointed Director Emeritus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alice N. Schwartz, co-founder and director, will not stand for re-election at the 2022 Annual Meeting.","Board appointed Schwartz as Director Emeritus effective April 26, 2022; role is non-voting and unpaid.","Director Emeritus may attend board meetings and receive materials at company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385719,"accession_number":"0001193125-22-063143","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Rad closes $1.2B senior notes offering (3.300% 2027 & 3.700% 2032)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M 3.300% notes due 2027 and $800M 3.700% notes due 2032 issued at par.","Net proceeds of approximately $1.186 billion after underwriting discount and expenses.","Proceeds for general corporate purposes, including working capital, capex, and potential M&A.","Joint book-runners: Citigroup Global Markets, Goldman Sachs, J.P. Morgan Securities.","Closing date March 2, 2022; offering pursuant to shelf registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385718,"accession_number":"0001193125-22-053527","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.","Adjusted EBITDA margin target of 28% in 2025, up from 20%+ target set in 2017.","Previously set 2017 targets of 3-5% revenue growth and 20%+ EBITDA margin were exceeded.","Growth drivers include ddPCR, single cell analysis, biopharma expansion, and molecular diagnostics.","Capital allocation strategy includes generating cash flow and pursuing strategic acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385717,"accession_number":"0000012208-22-000005","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q4 revenue down 7.2% to $733M; GAAP loss $52.59/sh, non-GAAP EPS $3.21; 2022 outlook 1-2% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 sales $732.8M (-7.2% YoY); Life Science sales down 23.8% on lower COVID-related qPCR demand.","GAAP net loss $1,573.7M ($52.59 loss per diluted share) vs net income $839.1M in Q4 2020, impacted by Sartorius AG fair value changes.","Non-GAAP net income $97.0M ($3.21 per share) vs $121.0M ($4.01) in Q4 2020.","Full year 2021 sales $2,922.5M (+14.8% reported); core revenue ex-COVID up 17.0% currency-neutral.","2022 guidance: non-GAAP currency-neutral revenue growth 1-2%, non-GAAP operating margin ~19.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":140.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":2922500000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403610,"accession_number":"0001193125-21-342427","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio-Rad loans €400M to Sartorius-Herbst at 1.5% plus appreciation rights","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of €400 million to Sartorius-Herbst Beteiligungen II GmbH at 1.5% per annum plus value appreciation rights.","Maturity on January 31, 2029, subject to early termination provisions.","Proceeds used to partially finance acquisition of interests under the Sartorius Trust from another beneficiary.","Loan collateralized by pledge of trust interests under the Sartorius Trust."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403609,"accession_number":"0001193125-21-333913","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bio-Rad amends credit agreement to add LIBOR fallback, expand EBITDA definition, increase debt/asset sale baskets","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Adds LIBOR replacement language to credit agreement; updates benchmark provisions.","Expands EBITDA to include non-recurring cash expenses (transaction costs, milestone payments, restructuring).","Provides unlimited cash and cash equivalent basket measured against leverage ratio, net of cash up to $200M globally.","Increases baskets for indebtedness, asset sales, cross-defaults, and judgment liens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403608,"accession_number":"0000012208-21-000045","cik":12208,"company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).","GAAP net income $3.93B ($129.96 diluted EPS) driven by $4.87B unrealized gain on Sartorius equity.","Non-GAAP net income $112.2M ($3.71 diluted EPS) vs $90.3M ($3.00) a year ago.","Full-year 2021 guidance: non-GAAP currency-neutral revenue growth 12-13%; operating margin ~19.5%.","Gross margin improved to 58.6% from 56.7%; operating margin 21.0% vs 16.9%."],"consensus_eps_estimate":null,"consensus_eps_actual":192.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2189776000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8222270696.869687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-28T23:59:59+00:00|403608"}